Lansoprazole
Product Images NDC 16714-186

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 16714-186). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton1 (Carton1)

Packaging label for Lansoprazole 15 mg delayed-release orally disintegrating tablets by NorthStar Rx LLC. The carton contains 100 tablets, divided into 10 packs of 10 each. The label includes administration instructions with images, storage instructions, and manufacturer details indicating Dr. Reddy's Laboratories Limited in India.*

FDA Label Image

Carton2 (Carton2)

Packaging label for Lansoprazole 30 mg delayed-release orally disintegrating tablets by NorthStar Rx LLC. The label indicates 100 tablets per container in 10 packs of 10 tablets. Manufacturing information shows Mfd. by Dr. Reddy's Laboratories Limited, India. The label includes usage instructions with illustrations, storage conditions, and a warning to dispense the Medication Guide to patients.*

FDA Label Image

Figure1 (Figure1)

A line graph showing the mean severity of day heartburn by study day for evaluable patients, with severity levels from 0 (none) to 3 (severe). It compares placebo, lansoprazole 15 mg QD, and lansoprazole 30 mg QD across approximately 60 days from the start of treatment, illustrating decreased heartburn severity over time with lansoprazole treatment compared to placebo.*

FDA Label Image

Figure2 (Figure2)

A line graph showing the mean severity of night heartburn over days from the start of treatment for evaluable patients. The graph compares placebo, Lansoprazole 15 mg once daily, and Lansoprazole 30 mg once daily, with severity measured on a scale from 0 (None) to 3 (Severe). The Lansoprazole groups show a downward trend in heartburn severity compared to placebo over approximately 60 days.*

FDA Label Image

Logo (Logo)

Chemical structure diagram of Lansoprazole, showing its molecular arrangement and bonds. The illustration captures the detailed representation of Lansoprazole's chemical form as submitted in the FDA Structured Product Labeling.*

FDA Label Image

Structure (Structure)

Chemical structure of lansoprazole, showing its molecular components including a benzimidazole ring, sulfoxide, and substituted pyridine group with trifluoromethoxy substitution.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.